The 2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the Use of Biologic Agents recommends tuberculosis (TB) screening before using biologic agents to identify latent TB infection (LTBI)¹. The ACR recommends the tuberculin skin test or interferon-γ release assays as the initial test in all patients starting biologic agents, regardless of risk factors for LTBI. Of newly diagnosed psoriatic arthritis patients, 96.3% in 2016 (78 of 81), 95.6% in 2017 (86 of 90), 94.8% in 2018 (100 of 116), 86.3% in 2019 (63 of 73), and 96.1% in 2020 (74 of 77) had TB testing.
¹Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012 May;64(5):625-639.